Ascendis Pharma sells YORVIPATH for hypoparathyroidism and SKYTROFA for growth hormone deficiency, and launched YUVIWEL for achondroplasia in the U.S.; YUVIWEL awaits an EU decision.
Ascendis sells three rare-disease drugs. YORVIPATH drove EUR 252 million of second-quarter sales, SKYTROFA EUR 55 million and the new YUVIWEL EUR 8 million. YUVIWEL, a weekly treatment for children with achondroplasia, won a positive CHMP opinion; the EU decision is expected in the fourth quarter. Settling with BioMarin ended the patent fight but costs royalties of 20% on U.S. and 18% on EU YUVIWEL sales through May 2030. Ascendis now generates cash and held EUR 812 million at June 30.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: EU approves YUVIWEL
Does the European Commission approve YUVIWEL for children with achondroplasia?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
YUVIWEL won a positive EU opinion; BioMarin royalties cut its margin through 2030
YUVIWEL approved and generating revenue, but a 20% BioMarin royalty burden tests whether achondroplasia economics support the combination therapy ambition
YUVIWEL approved and accelerating, but a 20% BioMarin royalty burden tests whether achondroplasia economics sustain the platform's ambitions
First CNP therapy approved for achondroplasia, launching commercially, but full approval hinges on confirmatory trial data the FDA has not yet seen
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Eye diseases, Obesity, diabetes and heart disease, Endocrine and bone diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
7 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.